Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 67

1.

Allogeneic stem cell transplantation for myelofibrosis patients aged ≥65 years.

Daghia G, Zabelina T, Zeck G, von Pein UM, Christopeit M, Wolschke C, Ayuk F, Kröger N.

Eur J Haematol. 2019 Jul 15. doi: 10.1111/ejh.13294. [Epub ahead of print]

PMID:
31306511
2.

Assessment of Quality of Life following Allogeneic Stem Cell Transplant for Myelofibrosis.

Palmer J, Kosiorek HE, Wolschke C, Fauble VDS, Butterfield R 3rd, Geyer H, Scherber RM, Dueck AC, Gathany A, Mesa RA, Kroger N.

Biol Blood Marrow Transplant. 2019 Jul 6. pii: S1083-8791(19)30433-1. doi: 10.1016/j.bbmt.2019.07.001. [Epub ahead of print]

PMID:
31288096
3.

Myeloablative and Reduced-Intensity Conditioned Allogeneic Hematopoietic Stem Cell Transplantation in Myelofibrosis: A Retrospective Study by the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation.

McLornan D, Szydlo R, Koster L, Chalandon Y, Robin M, Wolschke C, Beelen D, Socié G, Bornhäuser M, Angelucci E, Niederwieser D, Gerbitz A, Finke J, Vitek A, Itälä-Remes M, Radujkovic A, Kanz L, Potter V, Chevallier P, Stelljes M, Petersen E, Robinson S, Poiré X, Klyuchnikov E, Hernández-Boluda JC, Czerw T, Hayden P, Kröger N, Yakoub-Agha I.

Biol Blood Marrow Transplant. 2019 Jul 5. pii: S1083-8791(19)30418-5. doi: 10.1016/j.bbmt.2019.06.034. [Epub ahead of print]

PMID:
31284069
4.

Reduced intensity allogeneic stem cell transplantation for younger patients with myelofibrosis.

Mannina D, Zabelina T, Wolschke C, Heinzelmann M, Triviai I, Christopeit M, Badbaran A, Bonmann S, von Pein UM, Janson D, Ayuk F, Kröger N.

Br J Haematol. 2019 Aug;186(3):484-489. doi: 10.1111/bjh.15952. Epub 2019 May 15.

PMID:
31090920
5.

[Pancytopenia of unknown origin in a 52-year-old patient].

Heidenreich S, van Randenbourgh A, Ayuk F, Kröger N, Schmiedel S, Asemissen A, Oelrich J, Wolschke C.

Internist (Berl). 2019 Aug;60(8):867-870. doi: 10.1007/s00108-019-0596-5. German.

PMID:
30969356
6.

Comparison of Dynamic International Prognostic Scoring System and MYelofibrosis SECondary to PV and ET Prognostic Model for Prediction of Outcome in Polycythemia Vera and Essential Thrombocythemia Myelofibrosis after Allogeneic Stem Cell Transplantation.

Gagelmann N, Eikema DJ, de Wreede LC, Koster L, Wolschke C, Arnold R, Kanz L, McQuaker G, Marchand T, Socié G, Bourhis JH, Mohty M, Cornelissen JJ, Chevallier P, Bernasconi P, Stelljes M, Rohrlich PS, Fanin R, Finke J, Maertens J, Blaise D, Itälä-Remes M, Labussière-Wallet H, Robin M, McLornan D, Chalandon Y, Yakoub-Agha I, Kröger N; CMWP of the European Society for Blood and Marrow Transplantation.

Biol Blood Marrow Transplant. 2019 Jun;25(6):e204-e208. doi: 10.1016/j.bbmt.2019.03.024. Epub 2019 Mar 28.

PMID:
30930192
7.

Impact of primary disease on outcome after allogeneic stem cell transplantation for transformed secondary acute leukaemia.

Kröger N, Eikema DJ, Köster L, Beelen D, de Wreede LC, Finke J, Koenecke C, Niederwieser D, Bornhäuser M, Schoenland S, Potter V, Wolschke C, Maertens J, Theobald M, Kobbe G, Itälä-Remes M, Wulf G, Kahls P, Forcade E, Greinix H, Masszi T, Yakoub-Agha I, Chalandon Y, Robin M; Chronic Malignancies Working Party of the European Society for Blood Marrow Transplantation.

Br J Haematol. 2019 May;185(4):725-732. doi: 10.1111/bjh.15819. Epub 2019 Feb 28.

PMID:
30820933
8.

Long-term outcome after allogeneic hematopoietic cell transplantation for myelofibrosis.

Robin M, de Wreede LC, Wolschke C, Schetelig J, Eikema DJ, Van Lint MT, Knelange NS, Beelen D, Brecht A, Niederwieser D, Vitek A, Bethge W, Arnold R, Finke J, Volin L, Yakoub-Agha I, Nagler A, Poiré X, Einsele H, Chevallier P, Holler E, Ljungman P, Robinson S, Radujkovic A, McLornan D, Chalandon Y, Kröger N.

Haematologica. 2019 Sep;104(9):1782-1788. doi: 10.3324/haematol.2018.205211. Epub 2019 Feb 7.

9.

Acute GVHD prophylaxis plus ATLG after myeloablative allogeneic haemopoietic peripheral blood stem-cell transplantation from HLA-identical siblings in patients with acute myeloid leukaemia in remission: final results of quality of life and long-term outcome analysis of a phase 3 randomised study.

Bonifazi F, Solano C, Wolschke C, Sessa M, Patriarca F, Zallio F, Nagler A, Selleri C, Risitano AM, Messina G, Bethge W, Herrera P, Sureda A, Carella AM, Cimminiello M, Guidi S, Finke J, Sorasio R, Ferra C, Sierra J, Russo D, Benedetti E, Milone G, Benedetti F, Heinzelmann M, Pastore D, Jurado M, Terruzzi E, Narni F, Völp A, Ayuk F, Ruutu T, Kröger N.

Lancet Haematol. 2019 Feb;6(2):e89-e99. doi: 10.1016/S2352-3026(18)30214-X. Erratum in: Lancet Haematol. 2019 Mar;6(3):e121.

PMID:
30709437
10.

Antilymphocyte globulin for matched sibling donor transplantation in patients with myelofibrosis.

Robin M, Chevret S, Koster L, Wolschke C, Yakoub-Agha I, Bourhis JH, Chevallier P, Cornelissen JJ, Reményi P, Maertens J, Poiré X, Craddock C, Socié G, Itälä-Remes M, Schouten HC, Marchand T, Passweg J, Blaise D, Damaj G, Ozkurt ZN, Zuckerman T, Cluzeau T, Labussière-Wallet H, Cammenga J, McLornan D, Chalandon Y, Kröger N.

Haematologica. 2019 Jun;104(6):1230-1236. doi: 10.3324/haematol.2018.201400. Epub 2019 Jan 17.

11.

HLA-Mismatched Donors in Patients with Myelodysplastic Syndrome: An EBMT Registry Analysis.

Robin M, Porcher R, Ruggeri A, Blaise D, Wolschke C, Koster L, Angelucci E, Stölzel F, Potter V, Yakoub-Agha I, Koc Y, Ciceri F, Finke J, Labussière-Wallet H, Cascon MJP, Verbeek M, Rambaldi A, Cornelissen JJ, Chevallier P, Radia R, Nagler A, Fegueux N, Gluckman E, de Witte T, Kröger N.

Biol Blood Marrow Transplant. 2019 Jan;25(1):114-120. doi: 10.1016/j.bbmt.2018.08.026. Epub 2018 Aug 30.

PMID:
30172776
12.

Relative Impact of HLA Matching and Non-HLA Donor Characteristics on Outcomes of Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndrome.

Ayuk F, Beelen DW, Bornhäuser M, Stelljes M, Zabelina T, Finke J, Kobbe G, Wolff D, Wagner EM, Christopeit M, Schmid C, Ottinger H, Groth C, Faul C, Bertz H, Rachlis E, Wolschke C, Schetelig J, Horn PA, Mytilineos J, Guellstorf M, Kelsch R, Fleischhauer K, Kröger N, Bethge W.

Biol Blood Marrow Transplant. 2018 Dec;24(12):2558-2567. doi: 10.1016/j.bbmt.2018.06.026. Epub 2018 Jul 24.

PMID:
29966760
13.

Peritransplantation Ruxolitinib Prevents Acute Graft-versus-Host Disease in Patients with Myelofibrosis Undergoing Allogenic Stem Cell Transplantation.

Kröger N, Shahnaz Syed Abd Kadir S, Zabelina T, Badbaran A, Christopeit M, Ayuk F, Wolschke C.

Biol Blood Marrow Transplant. 2018 Oct;24(10):2152-2156. doi: 10.1016/j.bbmt.2018.05.023. Epub 2018 May 22.

PMID:
29800615
14.

Impact of ruxolitinib pretreatment on outcomes after allogeneic stem cell transplantation in patients with myelofibrosis.

Shahnaz Syed Abd Kadir S, Christopeit M, Wulf G, Wagner E, Bornhauser M, Schroeder T, Crysandt M, Mayer K, Jonas J, Stelljes M, Badbaran A, Ayuketang Ayuk F, Triviai I, Wolf D, Wolschke C, Kröger N.

Eur J Haematol. 2018 Sep;101(3):305-317. doi: 10.1111/ejh.13099. Epub 2018 Jul 4.

PMID:
29791053
15.

Long-Term Results of Prophylactic Donor Lymphocyte Infusions for Patients with Multiple Myeloma after Allogeneic Stem Cell Transplantation.

Gröger M, Gagelmann N, Wolschke C, von Pein UM, Klyuchnikov E, Christopeit M, Zander A, Ayuk F, Kröger N.

Biol Blood Marrow Transplant. 2018 Jul;24(7):1399-1405. doi: 10.1016/j.bbmt.2018.04.018. Epub 2018 Apr 21.

16.

Comparison of Different Rabbit Anti-Thymocyte Globulin Formulations in Allogeneic Stem Cell Transplantation: Systematic Literature Review and Network Meta-Analysis.

Gagelmann N, Ayuk F, Wolschke C, Kröger N.

Biol Blood Marrow Transplant. 2017 Dec;23(12):2184-2191. doi: 10.1016/j.bbmt.2017.08.027. Epub 2017 Aug 30. Review.

17.

Impact of molecular residual disease post allografting in myelofibrosis patients.

Wolschke C, Badbaran A, Zabelina T, Christopeit M, Ayuk F, Triviai I, Zander A, Alchalby H, Bacher U, Fehse B, Kröger N.

Bone Marrow Transplant. 2017 Nov;52(11):1526-1529. doi: 10.1038/bmt.2017.157. Epub 2017 Jul 17.

PMID:
28714945
18.

Impact of non-transferrin-bound iron (NTBI) in comparison to serum ferritin on outcome after allogeneic stem cell transplantation (ASCT).

Hilken A, Langebrake C, Wolschke C, Kersten JF, Rohde H, Nielsen P, Kröger N.

Ann Hematol. 2017 Aug;96(8):1379-1388. doi: 10.1007/s00277-017-3034-6. Epub 2017 Jun 6.

PMID:
28585071
19.

Long-term CD38 saturation by daratumumab interferes with diagnostic myeloma cell detection.

Oberle A, Brandt A, Alawi M, Langebrake C, Janjetovic S, Wolschke C, Schütze K, Bannas P, Kröger N, Koch-Nolte F, Bokemeyer C, Binder M.

Haematologica. 2017 Sep;102(9):e368-e370. doi: 10.3324/haematol.2017.169235. Epub 2017 May 18. No abstract available.

20.

Impact of Molecular Genetics on Outcome in Myelofibrosis Patients after Allogeneic Stem Cell Transplantation.

Kröger N, Panagiota V, Badbaran A, Zabelina T, Triviai I, Araujo Cruz MM, Shahswar R, Ayuk F, Gehlhaar M, Wolschke C, Bollin R, Walter C, Dugas M, Wiehlmann L, Lehmann U, Koenecke C, Chaturvedi A, Alchalby H, Stadler M, Eder M, Christopeit M, Göhring G, Koenigsmann M, Schlegelberger B, Kreipe HH, Ganser A, Stocking C, Fehse B, Thol F, Heuser M.

Biol Blood Marrow Transplant. 2017 Jul;23(7):1095-1101. doi: 10.1016/j.bbmt.2017.03.034. Epub 2017 Apr 4.

21.

Suspected encephalitis with Candida tropicalis and Fusarium detected by unbiased RNA sequencing.

Christopeit M, Grundhoff A, Rohde H, Belmar-Campos C, Grzyska U, Fiehler J, Wolschke C, Ayuk F, Kröger N, Fischer N.

Ann Hematol. 2016 Oct;95(11):1919-21. doi: 10.1007/s00277-016-2770-3. Epub 2016 Jul 29. No abstract available.

PMID:
27468852
22.

Similar outcome of calreticulin type I and calreticulin type II mutations following RIC allogeneic haematopoietic stem cell transplantation for myelofibrosis.

Christopeit M, Badbaran A, Zabelina T, Zeck G, Fehse B, Ayuk F, Wolschke C, Kröger N.

Bone Marrow Transplant. 2016 Oct;51(10):1391-1393. doi: 10.1038/bmt.2016.128. Epub 2016 May 23. No abstract available.

PMID:
27214077
23.

Outcome after Transplantation According to Reduced-Intensity Conditioning Regimen in Patients Undergoing Transplantation for Myelofibrosis.

Robin M, Porcher R, Wolschke C, Sicre de Fontbrune F, Alchalby H, Christopeit M, Cassinat B, Zabelina T, Peffault de Latour R, Ayuk F, Socié G, Kröger N.

Biol Blood Marrow Transplant. 2016 Jul;22(7):1206-1211. doi: 10.1016/j.bbmt.2016.02.019. Epub 2016 Mar 10.

24.

Digital-PCR assay for screening and quantitative monitoring of calreticulin (CALR) type-2 positive patients with myelofibrosis following allogeneic stem cell transplantation.

Badbaran A, Fehse B, Christopeit M, Aranyossy T, Ayuk FA, Wolschke C, Kröger N.

Bone Marrow Transplant. 2016 Jun;51(6):872-3. doi: 10.1038/bmt.2016.14. Epub 2016 Feb 15. No abstract available.

PMID:
26878663
25.

Antilymphocyte Globulin for Prevention of Chronic Graft-versus-Host Disease.

Kröger N, Solano C, Wolschke C, Bandini G, Patriarca F, Pini M, Nagler A, Selleri C, Risitano A, Messina G, Bethge W, Pérez de Oteiza J, Duarte R, Carella AM, Cimminiello M, Guidi S, Finke J, Mordini N, Ferra C, Sierra J, Russo D, Petrini M, Milone G, Benedetti F, Heinzelmann M, Pastore D, Jurado M, Terruzzi E, Narni F, Völp A, Ayuk F, Ruutu T, Bonifazi F.

N Engl J Med. 2016 Jan 7;374(1):43-53. doi: 10.1056/NEJMoa1506002.

26.

Correlation of somatic mutations with outcome after FLAMSA-busulfan sequential conditioning and allogeneic stem cell transplantation in patients with myelodysplastic syndromes.

Christopeit M, Badbaran A, Alawi M, Zabelina T, Zeck G, Wolschke C, Ayuk F, Kröger N.

Eur J Haematol. 2016 Sep;97(3):288-96. doi: 10.1111/ejh.12724. Epub 2016 Feb 15.

PMID:
26680262
27.

Emergence of daptomycin non-susceptibility in colonizing vancomycin-resistant Enterococcus faecium isolates during daptomycin therapy.

Lellek H, Franke GC, Ruckert C, Wolters M, Wolschke C, Christner M, Büttner H, Alawi M, Kröger N, Rohde H.

Int J Med Microbiol. 2015 Dec;305(8):902-9. doi: 10.1016/j.ijmm.2015.09.005. Epub 2015 Sep 12.

PMID:
26454536
28.

Allogeneic stem cell transplantation after conditioning with treosulfan, etoposide and cyclophosphamide for patients with ALL: a phase II-study on behalf of the German Cooperative Transplant Study Group and ALL Study Group (GMALL).

Kröger N, Bornhäuser M, Stelljes M, Pichlmeier U, Trenschel R, Schmid C, Arnold R, Martin H, Heinzelmann M, Wolschke C, Meyer RG, Bethge W, Kobbe G, Ayuk F, Gökbuget N, Hölzer D, Zander A, Beelen D.

Bone Marrow Transplant. 2015 Dec;50(12):1503-7. doi: 10.1038/bmt.2015.202. Epub 2015 Sep 14.

PMID:
26367236
29.

Prognostic factors for survival of patients with newly diagnosed chronic GVHD according to NIH criteria.

Ayuk F, Veit R, Zabelina T, Bussmann L, Christopeit M, Alchalby H, Wolschke C, Lellek H, Bacher U, Zander AR, Kröger N.

Ann Hematol. 2015 Oct;94(10):1727-32. doi: 10.1007/s00277-015-2452-6. Epub 2015 Jul 24.

PMID:
26204824
30.

Atovaquone for Prophylaxis of Toxoplasmosis after Allogeneic Hematopoietic Stem Cell Transplantation.

Mendorf A, Klyuchnikov E, Langebrake C, Rohde H, Ayuk F, Regier M, Christopeit M, Zabelina T, Bacher A, Stübig T, Wolschke C, Bacher U, Kröger N.

Acta Haematol. 2015;134(3):146-54. doi: 10.1159/000380757. Epub 2015 May 5.

PMID:
25968483
31.

JAK1/2 inhibition impairs T cell function in vitro and in patients with myeloproliferative neoplasms.

Parampalli Yajnanarayana S, Stübig T, Cornez I, Alchalby H, Schönberg K, Rudolph J, Triviai I, Wolschke C, Heine A, Brossart P, Kröger N, Wolf D.

Br J Haematol. 2015 Jun;169(6):824-33. doi: 10.1111/bjh.13373. Epub 2015 Mar 30.

PMID:
25824483
32.

Dynamic of bone marrow fibrosis regression predicts survival after allogeneic stem cell transplantation for myelofibrosis.

Kröger N, Zabelina T, Alchalby H, Stübig T, Wolschke C, Ayuk F, von Hünerbein N, Kvasnicka HM, Thiele J, Kreipe HH, Büsche G.

Biol Blood Marrow Transplant. 2014 Jun;20(6):812-5. doi: 10.1016/j.bbmt.2014.02.019. Epub 2014 Mar 1.

33.

JAK inhibition with ruxolitinib as pretreatment for allogeneic stem cell transplantation in primary or post-ET/PV myelofibrosis.

Stübig T, Alchalby H, Ditschkowski M, Wolf D, Wulf G, Zabelina T, Wolschke C, Ayuk F, Kröger N.

Leukemia. 2014 Aug;28(8):1736-8. doi: 10.1038/leu.2014.86. Epub 2014 Feb 26. No abstract available.

PMID:
24569777
34.

Micafungin as antifungal prophylaxis in recipients of allogeneic hematopoietic stem cell transplantation: results of different dosage levels in clinical practice.

Langebrake C, Rohde H, Lellek H, Wolschke C, Kröger NM.

Clin Transplant. 2014 Mar;28(3):286-91. doi: 10.1111/ctr.12310. Epub 2014 Jan 30.

PMID:
24479680
35.

CD34(+)-selected stem cell boost without further conditioning for poor graft function after allogeneic stem cell transplantation in patients with hematological malignancies.

Klyuchnikov E, El-Cheikh J, Sputtek A, Lioznov M, Calmels B, Furst S, Chabannon C, Crocchiolo R, Lemarié C, Faucher C, Bacher U, Alchalby H, Stübig T, Wolschke C, Ayuk F, Reckhaus ML, Blaise D, Kröger N.

Biol Blood Marrow Transplant. 2014 Mar;20(3):382-6. doi: 10.1016/j.bbmt.2013.11.034. Epub 2013 Dec 7.

36.

Serum albumin level predicts survival of patients with gastrointestinal acute graft-versus-host disease after allogeneic stem cell transplantation.

Ayuk F, Bussmann L, Zabelina T, Veit R, Alchalby H, Wolschke C, Lellek H, Bacher U, Zander AR, Kröger N.

Ann Hematol. 2014 May;93(5):855-61. doi: 10.1007/s00277-013-1957-0. Epub 2013 Nov 19.

PMID:
24248672
37.

Postallogeneic monitoring with molecular markers detected by pretransplant next-generation or Sanger sequencing predicts clinical relapse in patients with myelodysplastic/myeloproliferative neoplasms.

Fu Y, Schroeder T, Zabelina T, Badbaran A, Bacher U, Kobbe G, Ayuk F, Wolschke C, Schnittger S, Kohlmann A, Haferlach T, Kröger N.

Eur J Haematol. 2014 Mar;92(3):189-94. doi: 10.1111/ejh.12223. Epub 2013 Nov 21.

PMID:
24164563
38.

Effective prevention of GVHD using in vivo T-cell depletion with anti-lymphocyte globulin in HLA-identical or -mismatched sibling peripheral blood stem cell transplantation.

Wolschke C, Zabelina T, Ayuk F, Alchalby H, Berger J, Klyuchnikov E, Pein UM, Schumacher S, Amtsfeld G, Adjallé R, Wortmann F, Lellek H, Randenborgh A, Zander A, Kröger N.

Bone Marrow Transplant. 2014 Jan;49(1):126-30. doi: 10.1038/bmt.2013.143. Epub 2013 Sep 16.

PMID:
24037022
39.

Donor choice according to age for allo-SCT for AML in complete remission.

Ayuk F, Zabelina T, Wortmann F, Alchalby H, Wolschke C, Lellek H, Bacher U, Zander A, Kröger N.

Bone Marrow Transplant. 2013 Aug;48(8):1028-32. doi: 10.1038/bmt.2013.14. Epub 2013 Feb 18.

PMID:
23419435
40.

Azacitidine and donor lymphocyte infusions as first salvage therapy for relapse of AML or MDS after allogeneic stem cell transplantation.

Schroeder T, Czibere A, Platzbecker U, Bug G, Uharek L, Luft T, Giagounidis A, Zohren F, Bruns I, Wolschke C, Rieger K, Fenk R, Germing U, Haas R, Kröger N, Kobbe G.

Leukemia. 2013 Jun;27(6):1229-35. doi: 10.1038/leu.2013.7. Epub 2013 Jan 14.

PMID:
23314834
41.

Outcome of allogeneic SCT in patients with chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy.

Oyekunle A, Zander AR, Binder M, Ayuk F, Zabelina T, Christopeit M, Stübig T, Alchalby H, Schafhausen P, Lellek H, Wolschke C, Müller I, Bacher U, Kröger N.

Ann Hematol. 2013 Apr;92(4):487-96. doi: 10.1007/s00277-012-1650-8. Epub 2012 Dec 19.

PMID:
23250623
42.

Postallograft lenalidomide induces strong NK cell-mediated antimyeloma activity and risk for T cell-mediated GvHD: Results from a phase I/II dose-finding study.

Wolschke C, Stübig T, Hegenbart U, Schönland S, Heinzelmann M, Hildebrandt Y, Ayuk F, Atanackovic D, Dreger P, Zander A, Kröger N.

Exp Hematol. 2013 Feb;41(2):134-142.e3. doi: 10.1016/j.exphem.2012.10.004. Epub 2012 Oct 17.

PMID:
23085463
43.

Impact of high-risk cytogenetics and achievement of molecular remission on long-term freedom from disease after autologous-allogeneic tandem transplantation in patients with multiple myeloma.

Kröger N, Badbaran A, Zabelina T, Ayuk F, Wolschke C, Alchalby H, Klyuchnikov E, Atanackovic D, Schilling G, Hansen T, Schwarz S, Heinzelmann M, Zeschke S, Bacher U, Stübig T, Fehse B, Zander AR.

Biol Blood Marrow Transplant. 2013 Mar;19(3):398-404. doi: 10.1016/j.bbmt.2012.10.008. Epub 2012 Oct 16.

44.

Donor lymphocyte infusions and second transplantation as salvage treatment for relapsed myelofibrosis after reduced-intensity allografting.

Klyuchnikov E, Holler E, Bornhäuser M, Kobbe G, Nagler A, Shimoni A, Könecke C, Wolschke C, Bacher U, Zander AR, Kröger N.

Br J Haematol. 2012 Oct;159(2):172-81. doi: 10.1111/bjh.12013. Epub 2012 Aug 22.

PMID:
22909192
45.

Toxicity-reduced, myeloablative allograft followed by lenalidomide maintenance as salvage therapy for refractory/relapsed myeloma patients.

Kröger N, Zabelina T, Klyuchnikov E, Kropff M, Pflüger KH, Burchert A, Stübig T, Wolschke C, Ayuk F, Hildebrandt Y, Bacher U, Badbaran A, Schilling G, Hansen T, Atanackovic D, Zander AR.

Bone Marrow Transplant. 2013 Mar;48(3):403-7. doi: 10.1038/bmt.2012.142. Epub 2012 Aug 6.

PMID:
22863722
46.

18F-FDG PET/CT for detection and localization of residual or recurrent disease in patients with multiple myeloma after stem cell transplantation.

Derlin T, Weber C, Habermann CR, Herrmann J, Wisotzki C, Ayuk F, Wolschke C, Klutmann S, Kröger N.

Eur J Nucl Med Mol Imaging. 2012 Mar;39(3):493-500. doi: 10.1007/s00259-011-1993-8. Epub 2011 Nov 24.

PMID:
22113619
47.

Second allogeneic stem cell transplantation in a patient with hypoplastic myelodysplastic syndrome following a primary diagnosis of aplastic anaemia.

Ocheni S, Oyekunle A, Kröger N, Ayuk F, Klyuchnikov E, Arps S, Held K, Zabelina T, Adjallé R, Wolschke C, Zander AR, Bacher U.

Acta Haematol. 2011;125(3):175-8. doi: 10.1159/000322609. Epub 2010 Dec 30. No abstract available.

PMID:
21196720
48.

Caspofungin plus posaconazole as salvage therapy of invasive fungal infections in immunocompromised patients.

Lellek H, Waldenmaier D, Dahlke J, Ayuk FA, Wolschke C, Kröger N, Zander AR.

Mycoses. 2011 Jan;54 Suppl 1:39-44. doi: 10.1111/j.1439-0507.2010.01985.x.

PMID:
21126271
49.

Chimerism studies with quantitative real-time PCR in stem cell recipients with acute myeloid leukemia.

Wiedemann B, Klyuchnikov E, Kröger N, Zabelina T, Stahl T, Zeschke S, Badbaran A, Ayuk F, Alchalby H, Wolschke C, Bokemeyer C, Fehse B, Zander AR, Bacher U.

Exp Hematol. 2010 Dec;38(12):1261-71. doi: 10.1016/j.exphem.2010.08.006. Epub 2010 Sep 17.

PMID:
20851159
50.

Minimal residual disease diagnostics in patients with acute myeloid leukemia in the post-transplant period: comparison of peripheral blood and bone marrow analysis.

Stahl T, Badbaran A, Kröger N, Klyuchnikov E, Zabelina T, Zeschke S, Schafhausen P, Schultz W, Asenova S, Smirnova A, Wolschke C, Ayuk F, Zander AR, Fehse B, Bacher U.

Leuk Lymphoma. 2010 Oct;51(10):1837-43. doi: 10.3109/10428194.2010.508822.

PMID:
20849383

Supplemental Content

Loading ...
Support Center